Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor
Ver/Abrir
Use este enlace para citar
http://hdl.handle.net/2183/21551
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España
Colecciones
- GI-FENM - Artigos [119]
Metadatos
Mostrar el registro completo del ítemTítulo
Enzalutamide: a new prostate cancer targeted therapy against the androgen receptorAutor(es)
Fecha
2015-03Cita bibliográfica
Lázaro Quintela M, León Mateos L, Vázquez Estévez S, et al. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor. Cancer Treat Rev. 2015; 41(3):247-253
Resumen
[Abstract] Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer (mCRPC) who progressed to docetaxel. The anti-tumour activity and safety of enzalutamide has been demonstrated in a phase III clinical trial, showing a benefit in overall survival, which was the primary endpoint. There are no head-to-head studies comparing the different treatment options in this subset of patients. In this article, most relevant data published in the literature have been reviewed, with special attention to the therapeutic alternatives currently available for postdocexatel mCRPC patients, emphasising the mechanisms of action of the different drugs, efficacy and quality of life-related aspects.
Palabras clave
Enzalutamide
Metastatic castration-resistant prostate cancer
Abiraterone
Cabazitaxel
Docetaxel
Metastatic castration-resistant prostate cancer
Abiraterone
Cabazitaxel
Docetaxel
Versión del editor
Derechos
Atribución-NoComercial-SinDerivadas 3.0 España
ISSN
0305-7372